Evidence map›Paper›PMID 33512772›Full record

ArticleStem cells translational medicine2021

Neural crest-derived mesenchymal progenitor cells enhance cranial allograft integration.

Juliane D Glaeser, Phillip Behrens, Tina Stefanovic, Khosrowdad Salehi, Angela Papalamprou, Wafa Tawackoli, Melodie F Metzger, Samuel Eberlein, Trevor Nelson, Yasaman Arabi and 8 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. [Advances in Molecular Regulatory Mechanisms of Jaw Repair and Reconstruction].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  6. Article
  7. Directing iPSC differentiation into iTenocytes using combined scleraxis overexpression and cyclic loading.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Juliane D GlaeserOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Phillip BehrensOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Tina StefanovicOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Khosrowdad SalehiOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Angela PapalamprouOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Wafa TawackoliOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Melodie F MetzgerDepartment of Orthopedics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Samuel EberleinDepartment of Orthopedics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Trevor NelsonDepartment of Orthopedics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Yasaman ArabiOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kevin KimBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Robert H BalohBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Shiran Ben-DavidBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Doron Cohn-SchwartzDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Robert RyuOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Hyun W BaeOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Zulma GazitBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0001-9176-0889
Dmitriy SheynOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0002-3333-1485
Cedars-Sinai Medical Center · USRambam Health Care Campus · IL

Funding

Induced pluripotent stem cell therapy for degenerated IVDK01AR071512 · NIAMS · CEDARS-SINAI MEDICAL CENTER · PI SHEYN, DMITRIY · 2018 to 2022
$595k
NIAMS NIH HHS K01 AR071512
6 · The paper itself

Abstract

Replacement of lost cranial bone (partly mesodermal and partly neural crest-derived) is challenging and includes the use of nonviable allografts. To revitalize allografts, bone marrow-derived mesenchymal stromal cells (mesoderm-derived BM-MSCs) have been used with limited success. We hypothesize that coating of allografts with induced neural crest cell-mesenchymal progenitor cells (iNCC-MPCs) improves implant-to-bone integration in mouse cranial defects. Human induced pluripotent stem cells were reprogramed from dermal fibroblasts, differentiated to iNCCs and then to iNCC-MPCs. BM-MSCs were used as reference. Cells were labeled with luciferase (Luc2) and characterized for MSC consensus markers expression, differentiation, and risk of cellular transformation. A calvarial defect was created in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice and allografts were implanted, with or without cell coating. Bioluminescence imaging (BLI), microcomputed tomography (μCT), histology, immunofluorescence, and biomechanical tests were performed. Characterization of iNCC-MPC-Luc2 vs BM-MSC-Luc2 showed no difference in MSC markers expression and differentiation in vitro. In vivo, BLI indicated survival of both cell types for at least 8 weeks. At week 8, μCT analysis showed enhanced structural parameters in the iNCC-MPC-Luc2 group and increased bone volume in the BM-MSC-Luc2 group compared to controls. Histology demonstrated improved integration of iNCC-MPC-Luc2 allografts compared to BM-MSC-Luc2 group and controls. Human osteocalcin and collagen type 1 were detected at the allograft-host interphase in cell-seeded groups. The iNCC-MPC-Luc2 group also demonstrated improved biomechanical properties compared to BM-MSC-Luc2 implants and cell-free controls. Our results show an improved integration of iNCC-MPC-Luc2-coated allografts compared to BM-MSC-Luc2 and controls, suggesting the use of iNCC-MPCs as potential cell source for cranial bone repair.

Indexed as

Bone-Implant InterfaceInduced Pluripotent Stem CellsMesenchymal Stem CellsAllograftsAnimalsBone Marrow CellsCell DifferentiationHumansMesenchymal Stem Cell TransplantationMiceMice, Inbred NODMice, SCIDNeural CrestOsseointegrationSkullX-Ray Microtomographyallograftbone healingcranial repairMSCneural crest cells

Identifiers

PMID33512772
PMCPMC8046069
OpenAlexW3124331250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.